Wednesday 10 September 2008

DUI Plea All Greek to TV Star

The maven of Greek may be in for a bit of a hazing by the Los Angeles City Attorney's Office.


Scott Michael Foster, who plays Cappie on the ABC Family express, has pleaded not guilty to iI misdemeanor counts of driving under the influence stemming from his bust earlier this summer.


The 23-year-old small-screen frat boy was arrested in the early hours of July 21 after failing a field sobriety test issued during a routine traffic stop. He was supercharged with driving under the influence and driving with a blood-alcohol level of 0.08 percent or above.


He was released after several hours on $5,000 bail and headed straight to the Greek set, where he was quick to issue mea culpas to his confrere cast and crew.


He's clearly got some school heart. Time will tell if he's besides got a good defense.


A pretrial earshot has been set for Sept. 22.










More info

Sunday 31 August 2008

Long Term Safety Profile Of Symbicort Analyzed In Asthma Patients

�A 52-week study examined the long-term safety of the upkeep combination asthma therapy, SYMBICORT� (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol, at up to double the approved dose.1 More than 700 patients ages 12 years and elderly with tone down to grievous persistent asthma, and wHO had been previously toughened with inhaled corticosteroids, participated in the study.1 Safety was evaluated through several assessments, including the incidence of asthma exacerbations and inauspicious events.1 The study showed that SYMBICORT, a combination of budesonide, an inhaled corticoid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA), had a safety profile like to 1 of its mono-components, budesonide.1,2 Results were published online and will be a part of the September-October issue of Allergy and Asthma Proceedings.


"In this survey, no significant or unexpected adverse events were ascertained when combination formoterol, a long-acting beta2-agonist, with budesonide for up to one year,"1 said written report investigator, Bruce Prenner, MD, University of California, San Diego in La Jolla, California. "The safety information obtained during this cogitation are reassuring and in line with NIH guidelines recommending combination therapy, such as SYMBICORT, for patients whose consideration requires more than than inhaled corticosteroids alone."1,3

About the Study Results


The study demonstrated that the percentage of patients with at least one asthma exacerbation was significantly lower (p=0.006) with four-spot inhalations twice-daily of SYMBICORT 160/4.5 mcg (12.2%) and numerically lour (p=0.117) with two inhalations twice-daily of SYMBICORT 160/4.5 mcg (14.4%) versus four inhalations twice day-by-day of budesonide 160 microgram (21.8%).1 In the U.S., SYMBICORT is not approved for manipulation as quatern inhalations twice-daily and is only sanctioned for habit as two inhalations twice-daily. 2 The proportion of asthma exacerbations per patient-treatment year was significantly glower with both doses of SYMBICORT (0.174, p=0.004, quadruplet inhalations; 0.185, p=0.049, two inhalations) compared to budesonide (0.315).1 The number of patients with at least one hospitalization, emergency department or pressing care call in due to an bronchial asthma exacerbation was not statistically significantly different between the treatment groups.1 In addition, no clinically meaningful differences in laboratory, eCG, or Holter monitor (records heart's electrical activity4) variables were ascertained between groups.1


Results also demonstrated that SYMBICORT was well tolerated for up to 52 weeks.1 The percentages of patients wHO experienced whatever adverse events were similar for both dosing blazon of SYMBICORT (88.9%, four inhalations; 84.1%, two inhalations) and budesonide (88.7%).1 Adverse events were mainly mild or moderate in vividness.1 The most coarse drug-related adverse events, as judged by the investigators, (>2% overall) included oral candidiasis (9.7%), tremor (3.2%) and pharyngolaryngeal pain (2.0%).1 Patient discontinuance rates due to drug-related adverse events were scummy and like across all treatment groups.1


"The safety profile of SYMBICORT is based on a robust U.S. development political platform, which evaluated safety in over 6,000 patients treated with SYMBICORT in Phase I, II and III studies,"5 aforesaid Christopher O'Brien, MD, PhD, Senior Director, Medical Science, AstraZeneca. "AstraZeneca is committed to the safety of patients, and we continuously monitor the safety profiles of all our medications."

About the Study Design


The safety profile of SYMBICORT was assessed during a 52-week randomized, double-blind, parallel-group, single-dummy, multicenter Phase III study1 involving 708 patients ages 12 years and older with moderate to severe lasting asthma previously treated with ICS therapy,1 either alone or in combination.1 After a two-week run-in period when all patients were placed on two inhalations twice-daily budesonide pressurized metered-dose inhaler (pMDI) 160 micrograms (mcg) and, as needful, albuterol 90 mcg,1 patients were randomized 3:1:1 to receive either four inhalations twice-daily of SYMBICORT pMDI 160/4.5 mcg (N=443), which is twice its highest recommended dose, 2 2 inhalations twice-daily of SYMBICORT pMDI 160/4.5 microgram (N=132), or four inhalations twice-daily of budesonide pMDI 160 microgram (N=133).1


The study assessed patients at 8 visits over the 52-week period.1 Safety was evaluated based on the incidence of asthma exacerbations, defined as the use of oral or systemic corticosteroids, hospitalization, or an emergency section or pressing care visit due to asthma exacerbations, adverse events, serious inauspicious events and discontinuations ascribable to inauspicious events.1 Additional base hit assessments included laboratory evaluations, 24-hour urinary cortisol levels, vital signs, physical examinations, 12-lead electrocardiograms (ECGs), and 24-hour Holter monitoring.1 Adverse events were recorded in day-to-day logs reviewed at each study visit.1

About SYMBICORT


SYMBICORT is a combination therapy indicated for the long-term maintenance discussion of bronchial asthma in patients 12 age of historic period and sr..2 Administered twice everyday,2 SYMBICORT is a combination of two proved asthma medications budesonide, an inhaled corticoid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA).2 SYMBICORT does not replace fast-acting inhalers and should not be used to do by acute symptoms of asthma.2

Important Safety Information


Long acting beta2-adrenergic agonists may increase the risk of infection of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should exclusively be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants knowledgeability of handling with two maintenance therapies. Data from a turgid placebo-controlled U.S. study compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increment in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.
SYMBICORT is not indicated for the succor of acute bronchospasm.


SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.


Particular care is needed for patients world Health Organization are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency take occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.


Patients world Health Organization are receiving SYMBICORT twice daily should not consumption additional formoterol or other long-acting inhaled beta2-agonists for any reason.


Common adverse events reported in clinical trials, occurring in > 5 percent of patients, regardless of relationship to treatment, including nasopharyngitis, worry, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort.


For full Prescribing Information, please visit http://www.MySYMBICORT.com

About AstraZeneca


AstraZeneca is a major external healthcare business enterprise engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is ane of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit http://www.astrazeneca-us.com.

References


1. Peters, S.P., Prenner, B.M., Mezzanotte, W.S., Martin, P., O'Brien, C.D. Long-term ety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients.


2. Symbicort Prescribing Information.


3. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma.


4. National Heart, Lung, and Blood Institute. What Are Holter and Event Monitors? Retrieved on 28 July 2008. http://www.nhlbi.nih.gov/health/dci/Diseases/holt/holt_what.html.


5. Data on File, DA-SYM-01.


Edelman PR, NYC

New York, NY

United States
http://www.edelman.com



More info

Thursday 21 August 2008

U2 tracks leaked online after Bono boob

Four songs from U2's upcoming album were leaked on to the cyberspace after frontman Bono played them overly loudly on his stereoscopic photograph at his villa in the south of France.



A U2 fanatic from the Netherlands world Health Organization was holidaying in the village of Eze, on the French riviera, heard the new tracks being blared from Bono's window and distinct to record them exploitation his fluid phone.


The fan boasted about his find on the forum of U2 fansite Interference.com, and members at that place advised him to print the clips on YouTube.


The songs have since been removed from YouTube imputable to "right of first publication violations", most likely after a complaint from U2's longtime coach Paul McGuinness.


Interference, scared of legal repercussions, has forbidden the placard of golf links to the leaked songs on the forum simply members have begun trading them amongst themselves via email.


At the time of writing, the leaked clips - seen by Fairfax Media - could likewise be downloaded via the file sharing site Rapid Share.


The calibre is short and the beach lav be heard in the background just that hasn't deterred U2 fans keen for a teaser. The feedback on U2 discourse boards has so far been largely positive.


The new album, U2's number 1 in four-spot years, is expected to be titled No Line On The Horizon.


Based on the lyrics and other information already released, the four leaked songs appear to be named Moment of Surrender, For Your Love, Sexy Boots and No Line On The Horizon.


McGuiness lashed out at music pirates at an industry conference in January. He slammed internet service providers, saying they had "enjoyed a bonanza" in the last few years by accepting fees from illegal downloaders while doing nothing to prevent them from stealing music.


He called on ISPs to disconnect users wHO have been caught obtaining music illegally.


"Their snouts let been at our trough feeding justify for to a fault long," said McGuinness.


In 2004, tracks from U2's last album, How To Dismantle An Atomic Bomb, were leaked afterward a CD containing them were stolen from a photo shoot in the south of France.








More info

Monday 11 August 2008

The Datsuns to make UK live return

The Datsuns have announced details of their UK live return and new album.


The New Zealand retro-rockers will play the Camden Barfly in London on September 9 and Manchester's Night And Day Cafe on October 26, with more UK dates due to be announced.


The band's self-produced fourth album, 'Head Stunts', meanwhile, will be released on October 6, preceded by a individual, 'Human Error' on September 29.


�It's most mind games and self-distrust. 'Head Stunts' is an anagram of The Datsuns!� explained vocalist Dolf de Datsun.


To check the availability of The Datsuns tickets and go all the latest listings, go to NME.COM/GIGS now, or call 0871 230 1094.



More info

Wednesday 6 August 2008

N.S.PRAKASH RAO

N.S.PRAKASH RAO   
Artist: N.S.PRAKASH RAO

   Genre(s): 
Vocal
   



Discography:


SREE VISHNU SAHASRA NAMAM   
 SREE VISHNU SAHASRA NAMAM

   Year: 2000   
Tracks: 3


GAYATHRI MANTRAM   
 GAYATHRI MANTRAM

   Year: 1999   
Tracks: 1




 





Winehouse Wax Figure -- Crack Pipe Not Included

Wednesday 25 June 2008

Country Music Star Julie Roberts Joins Mothers Against Drunk Driving to Walk Like MADD to Eliminate Drunk Driving

Walkers Call on Nashville Leaders to Support Ignition Interlock
Legislation

See Interlock Technology in Action

NASHVILLE, Tenn., June 20 /PRNewswire-USNewswire/ -- Mothers Against
Drunk Driving (MADD) leadership will join Mercury Nashville recording
artist, Julie Roberts and 800 local supporters on Saturday, June 21 at
Centennial Park to participate in Walk Like MADD, a 5K non-competitive walk
that encourages the community to support MADD's Campaign to Eliminate Drunk
Driving. The walk comes at a time when nearly a third of all fatal crashes
on Tennessee's roadways involve a driver or motorcycle operator with a
blood alcohol concentration (BAC) of .08 or higher.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030421/MADDLOGO )

"The main reason people continue to drive drunk today - despite 27
years of intense public education and law enforcement's best efforts - is
because they can," said Glynn Birch, national president of MADD. "My son
might be here today if the offender that killed him had an interlock on his
vehicle." Birch's 21-month-old-son Courtney was killed 20 years ago on May
3, 1988, by a drunk driver with a blood alcohol level of .26 at the time of
the crash and was driving with a revoked license and three prior DUI
convictions.

According to the National Highway Traffic Safety Administration
(NHTSA), 408 people were killed in Tennessee in traffic crashes involving a
driver with a BAC of .08 or higher in 2006. Each year half a million others
are injured in alcohol-related traffic crashes nationally. A recent report
by the Substance Abuse and Mental Health Service Administration also
reported that 12.4 percent of Tennesseans admitted to driving under the
influence of alcohol at least once in the past year.

One proven method to reduce drunk driving is the installation of
alcohol ignition interlocks on convicted drunk drivers' vehicles. An
alcohol ignition interlock is a breath test device linked to a vehicle's
ignition system. Studies have shown alcohol ignition interlocks are up to
90 percent effective in reducing recidivism while installed on the vehicle.
If all states required alcohol ignition interlocks for all convicted drunk
drivers, we could save up to 4,000 lives a year.

"It is MADD's hope that during next year's legislative session, the
Tennessee legislature will pass a strong law for mandatory interlock use
for all convicted offenders, to prevent drunk drivers from committing this
crime again," said Alexanderia Honeycutt, the walk's organizer and MADD
Tennessee's senior development officer. "Drunk driving must end, and
together, we can make it happen."

Nashville's third annual Walk Like MADD event - formerly known as
Strides for Change - helps raise money and awareness to support MADD's
Campaign to Eliminate Drunk Driving, which calls for alcohol ignition
interlocks for all drunk drivers, as well as sobriety checkpoints and
saturation patrols.

The ceremonies will begin at 9:00 a.m. with the walk following at 9:30
a.m. on Saturday, June 21. Demonstrations of alcohol ignition interlocks
will be conducted immediately before and following the opening ceremony and
walkers will be encouraged to sign MADD's Campaign pledge.

"I feel so inspired by all of the walkers who have come out to support
MADD's mission to eliminate drunk driving," said Julie Roberts. "Their
participation is an incredible display of compassion and will go a long way
in preventing others from experiencing the pain of losing a loved one to
this violent crime."

This year, Walk Like MADD events take place in more than 30 cities
across the country. Corporations and individuals form teams of 10 or more
and are asked to raise $100 each through donations. Three ways to get
involved in the Nashville Walk Like MADD are:



-- If you live in the area of a walk event, register to walk or form a
team;
-- If you are unable to make one of the walks, sign up to raise money as a
virtual walker, anywhere and anytime; or
-- Give a one-time donation to the walks. Please visit http://www.walklikeMADD.org
to register, donate or get more information.
To learn more about MADD or to receive free victim services, please
visit http://www.madd.org or call (615) 360-8055. Victims/survivors of drunk
driving can call 1-877-MADD-HELP 24 hours a day, seven days a week, for
free victim services.

Walk Like MADD Event Information for Saturday, June 21, 2008

WHO: Glynn Birch, National President, MADD

Julie Roberts, Mercury Nashville Recording Artist

Cpt. Anthony Carter, Metropolitan Nashville Police Department

Laura Dial, Executive Director, MADD Tennessee

Alexanderia Honeycutt, Senior Development Officer, MADD Tennessee

Anna Marie, Host, Mix 92.9 Morning Show

WHEN: Saturday, June 21, 2008

Ceremonies Begin - 9:00 a.m.

Walk Begins - 9:30 a.m.

Interlock Demonstrations at 8:45 a.m., 9:45 a.m. and 10:00 a.m.

WHERE: Centennial Park

2600 West End Avenue

Nashville, TN 37203




See Also

Thursday 19 June 2008

Selma Blair - The Things They Say 8541


"I wanted to get Botox once to make me feel younger. But I don't really have to justify it yet." Actress SELMA BLAIR, 35.





See Also